This study is for kids and young adults with tumors that have come back or haven't responded to treatment. In this trial, participants will be divided into two groups, called Arm A and Arm B. Arm A will receive two medicines: Onivyde and talazoparib. Onivyde damages the cancer's DNA, while talazoparib stops the DNA from fixing itself, leading to cancer cell death. Arm B will use Onivyde and another medicine called temozolomide, both aiming to damage cancer DNA.
Once the right doses are found for each group, more kids will join to see if the treatments help their tumors disappear. If successful, a second phase will start, focusing on a specific cancer type called Ewing sarcoma. This study helps find the best dose and checks if the treatment works without causing too many side effects.
- The study involves multiple visits and treatments over up to 24 months.
- This study is for kids and young adults aged 12 months to 30 years.
- Participants are randomly assigned to receive different medicine combinations.